Logo image of DBVT

DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Fundamental Analysis

NASDAQ:DBVT - Nasdaq - US23306J2006 - ADR

4.55  +0.03 (+0.66%)

Fundamental Rating

3

Taking everything into account, DBVT scores 3 out of 10 in our fundamental rating. DBVT was compared to 572 industry peers in the Biotechnology industry. DBVT has a bad profitability rating. Also its financial health evaluation is rather negative. DBVT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DBVT has reported negative net income.
In the past year DBVT has reported a negative cash flow from operations.
DBVT had negative earnings in each of the past 5 years.
DBVT had a negative operating cash flow in each of the past 5 years.
DBVT Yearly Net Income VS EBIT VS OCF VS FCFDBVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -63.70%, DBVT is doing worse than 62.30% of the companies in the same industry.
Looking at the Return On Equity, with a value of -91.83%, DBVT is in line with its industry, outperforming 47.79% of the companies in the same industry.
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROIC N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
DBVT Yearly ROA, ROE, ROICDBVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

DBVT has a Gross Margin of 95.70%. This is amongst the best in the industry. DBVT outperforms 96.11% of its industry peers.
In the last couple of years the Gross Margin of DBVT has remained more or less at the same level.
DBVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
DBVT Yearly Profit, Operating, Gross MarginsDBVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DBVT has more shares outstanding
The number of shares outstanding for DBVT has been increased compared to 5 years ago.
DBVT has a worse debt/assets ratio than last year.
DBVT Yearly Shares OutstandingDBVT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
DBVT Yearly Total Debt VS Total AssetsDBVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

DBVT has an Altman-Z score of -0.56. This is a bad value and indicates that DBVT is not financially healthy and even has some risk of bankruptcy.
DBVT has a better Altman-Z score (-0.56) than 61.42% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that DBVT is not too dependend on debt financing.
The Debt to Equity ratio of DBVT (0.09) is worse than 65.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -0.56
ROIC/WACCN/A
WACC7.41%
DBVT Yearly LT Debt VS Equity VS FCFDBVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

DBVT has a Current Ratio of 3.29. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
DBVT has a worse Current ratio (3.29) than 61.24% of its industry peers.
DBVT has a Quick Ratio of 3.29. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
DBVT has a Quick ratio (3.29) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29
DBVT Yearly Current Assets VS Current LiabilitesDBVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.64% over the past year.
Looking at the last year, DBVT shows a very strong growth in Revenue. The Revenue has grown by 224.69%.
The Revenue has been growing slightly by 0.50% on average over the past years.
EPS 1Y (TTM)19.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%

3.2 Future

DBVT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.53% yearly.
The Revenue is expected to grow by 88.16% on average over the next years. This is a very strong growth
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y18.53%
Revenue Next Year-43.46%
Revenue Next 2Y309.09%
Revenue Next 3Y373.83%
Revenue Next 5Y88.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DBVT Yearly Revenue VS EstimatesDBVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DBVT Yearly EPS VS EstimatesDBVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBVT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBVT Price Earnings VS Forward Price EarningsDBVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBVT Per share dataDBVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

DBVT's earnings are expected to grow with 59.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.12%
EPS Next 3Y59.71%

More info and screens

0

5. Dividend

5.1 Amount

DBVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (1/22/2025, 11:40:19 AM)

4.55

+0.03 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2024-07-30/amc
Earnings (Next)N/A N/A
Inst Owners41.39%
Inst Owner Change-0.07%
Ins Owners0.15%
Ins Owner Change16.51%
Market Cap93.35M
Analysts82.86
Price Target9.27 (103.74%)
Short Float %2.62%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.87%
Min EPS beat(2)-68.32%
Max EPS beat(2)10.57%
EPS beat(4)3
Avg EPS beat(4)13.32%
Min EPS beat(4)-68.32%
Max EPS beat(4)67%
EPS beat(8)6
Avg EPS beat(8)-2.17%
EPS beat(12)8
Avg EPS beat(12)1.62%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-20.42%
Min Revenue beat(2)-29.38%
Max Revenue beat(2)-11.45%
Revenue beat(4)2
Avg Revenue beat(4)690.02%
Min Revenue beat(4)-29.38%
Max Revenue beat(4)2602.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.88%
PT rev (3m)160.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-368.96%
EPS NY rev (1m)0%
EPS NY rev (3m)-422.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-50%
Revenue NY rev (3m)-55.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.94
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-4.22
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)-5.04
FCFYN/A
OCF(TTM)-4.92
OCFYN/A
SpS0.77
BVpS3.86
TBVpS3.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.7%
FCFM N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 15.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -0.56
F-Score3
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)11.98%
Cap/Sales(5y)19.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y18.53%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%
Revenue Next Year-43.46%
Revenue Next 2Y309.09%
Revenue Next 3Y373.83%
Revenue Next 5Y88.16%
EBIT growth 1Y20.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.39%
EBIT Next 3Y56.49%
EBIT Next 5YN/A
FCF growth 1Y-50.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.06%
OCF growth 3YN/A
OCF growth 5YN/A